Coherus BioSciences. has filed a patent for a method of treating cancer by administering an anti-IL-27 antibody, atezolizumab, and bevacizumab to stimulate an immune response in a subject. The antibody includes specific amino acid sequences for effective treatment. GlobalData’s report on Coherus BioSciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Coherus BioSciences, Peptide nano-particle conjugates was a key innovation area identified from patents. Coherus BioSciences's grant share as of January 2024 was 31%. Grant share is based on the ratio of number of grants to total number of patents.
A patent application (Publication Number: US20240025987A1) describes a method for stimulating an immune response in a subject by administering an anti-IL-27 antibody, atezolizumab, and bevacizumab. The anti-IL-27 antibody includes specific amino acid sequences in its heavy and light chain CDRs. Additionally, the method extends to treating cancer in a subject by administering the same combination of the anti-IL-27 antibody, atezolizumab, and bevacizumab, with the antibody containing the specified amino acid sequences.
Furthermore, the patent application details the dosages and administration frequencies for the components, including the anti-IL-27 antibody, atezolizumab, and bevacizumab. The method allows for flexibility in dosing and administration schedules, providing options ranging from weekly to 12-week intervals. The application also specifies the amino acid sequences required for the anti-IL-27 antibody, ensuring a precise and targeted approach to stimulating an immune response and treating cancer, particularly hepatocellular carcinoma. Overall, the patent application outlines a comprehensive method for enhancing immune responses and treating cancer through the administration of specific antibodies and medications.
To know more about GlobalData’s detailed insights on Coherus BioSciences, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
